With completed Phase 1 and 2 clinical trials in non-small-cell lung cancer (NSCLC), BeyondSpring has a strong body of safety and efficacy data suggesting that a combination therapy of Plinabulin and commonly-used chemotherapy drug docetaxel can extend the overall survival of targeted late-stage NSCLC patients.
Based on consultation with the U.S. FDA, BeyondSpring are conduc